These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

469 related articles for article (PubMed ID: 36575346)

  • 1. Novel immunogenic cell death-related risk signature to predict prognosis and immune microenvironment in lung adenocarcinoma.
    Li Q; Tang Y; Wang T; Zhu J; Zhou Y; Shi J
    J Cancer Res Clin Oncol; 2023 Jan; 149(1):307-323. PubMed ID: 36575346
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identifying an immunogenic cell death-related gene signature contributes to predicting prognosis, immunotherapy efficacy, and tumor microenvironment of lung adenocarcinoma.
    Li X; Zhang D; Guo P; Ma S; Gao S; Li S; Yuan Y
    Aging (Albany NY); 2024 Apr; 16(7):6290-6313. PubMed ID: 38575204
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comprehensive analysis of the immunogenic cell death-related signature for predicting prognosis and immunotherapy efficiency in patients with lung adenocarcinoma.
    Cui Y; Li Y; Long S; Xu Y; Liu X; Sun Z; Sun Y; Hu J; Li X
    BMC Med Genomics; 2023 Aug; 16(1):184. PubMed ID: 37553698
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of molecular subtypes and prognostic model to reveal immune infiltration and predict prognosis based on immunogenic cell death-related genes in lung adenocarcinoma.
    Dong Y; Yu X; Song H; Chen Q; Zheng B; Ji X; Xu M; Liu J; Sun X; Wang Q; Ren R; Lu H
    Cell Cycle; 2023; 22(23-24):2566-2583. PubMed ID: 38164943
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An ICD-Associated DAMP Gene signature predicts survival and immunotherapy response of patients with lung adenocarcinoma.
    Wu Y; Li K; Liang S; Lou X; Li Y; Xu D; Wu Y; Wang Y; Cui W
    Respir Res; 2023 May; 24(1):142. PubMed ID: 37259066
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The integrated single-cell analysis developed an immunogenic cell death signature to predict lung adenocarcinoma prognosis and immunotherapy.
    Zhang P; Zhang H; Tang J; Ren Q; Zhang J; Chi H; Xiong J; Gong X; Wang W; Lin H; Li J; Huang C
    Aging (Albany NY); 2023 Oct; 15(19):10305-10329. PubMed ID: 37796202
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Leveraging diverse cell-death patterns to predict the clinical outcome of immune checkpoint therapy in lung adenocarcinoma: Based on muti-omics analysis and vitro assay.
    Liang H; Li Y; Qu Y; Zhang L
    Oncol Res; 2023; 32(2):393-407. PubMed ID: 38186574
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of immune activation-related gene signature for predicting prognosis and immunotherapy efficacy in lung adenocarcinoma.
    Zeng W; Wang J; Yang J; Chen Z; Cui Y; Li Q; Luo G; Ding H; Ju S; Li B; Chen J; Xie Y; Tong X; Liu M; Zhao J
    Front Immunol; 2023; 14():1217590. PubMed ID: 37492563
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunogenic cell death-related long noncoding RNA influences immunotherapy against lung adenocarcinoma.
    Sun D; Zhang C
    Oncol Res; 2023; 31(5):753-767. PubMed ID: 37547766
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular subtypes of lung adenocarcinoma patients for prognosis and therapeutic response prediction with machine learning on 13 programmed cell death patterns.
    Wei Q; Jiang X; Miao X; Zhang Y; Chen F; Zhang P
    J Cancer Res Clin Oncol; 2023 Oct; 149(13):11351-11368. PubMed ID: 37378675
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Classification related to immunogenic cell death predicts prognosis, immune microenvironment characteristics, and response to immunotherapy in lower-grade gliomas.
    Kuang Y; Jiang B; Zhu H; Zhou Y; Huang H; Li C; Zhang W; Li X; Cao Y
    Front Immunol; 2023; 14():1102094. PubMed ID: 37153540
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical Significance and Immunologic Landscape of a Five-IL(R)-Based Signature in Lung Adenocarcinoma.
    Fan T; Pan S; Yang S; Hao B; Zhang L; Li D; Geng Q
    Front Immunol; 2021; 12():693062. PubMed ID: 34497605
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of novel gene signature for lung adenocarcinoma by machine learning to predict immunotherapy and prognosis.
    Shu J; Jiang J; Zhao G
    Front Immunol; 2023; 14():1177847. PubMed ID: 37583701
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characteristic of molecular subtypes in lung adenocarcinoma based on m6A RNA methylation modification and immune microenvironment.
    Zhou H; Zheng M; Shi M; Wang J; Huang Z; Zhang H; Zhou Y; Shi J
    BMC Cancer; 2021 Aug; 21(1):938. PubMed ID: 34416861
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Integrated analysis of single-cell and bulk RNA-sequencing identifies a signature based on B cell marker genes to predict prognosis and immunotherapy response in lung adenocarcinoma.
    Song P; Li W; Wu X; Qian Z; Ying J; Gao S; He J
    Cancer Immunol Immunother; 2022 Oct; 71(10):2341-2354. PubMed ID: 35152302
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An immunogenic cell death-related signature predicts prognosis and immunotherapy response in stomach adenocarcinoma.
    Liu Z; Sun L; Peng X; Liu S; Zhu Z; Huang C
    Apoptosis; 2023 Dec; 28(11-12):1564-1583. PubMed ID: 37580435
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comprehensive analysis of a novel signature incorporating lipid metabolism and immune-related genes for assessing prognosis and immune landscape in lung adenocarcinoma.
    Wang Y; Xu J; Fang Y; Gu J; Zhao F; Tang Y; Xu R; Zhang B; Wu J; Fang Z; Li Y
    Front Immunol; 2022; 13():950001. PubMed ID: 36091041
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A novel immunogenic cell death-related genes signature for predicting prognosis, immune landscape and immunotherapy effect in hepatocellular carcinoma.
    Xu G; Jiang Y; Li Y; Ge J; Xu X; Chen D; Wu J
    J Cancer Res Clin Oncol; 2023 Dec; 149(18):16261-16277. PubMed ID: 37698679
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Subtype classification based on t cell proliferation-related regulator genes and risk model for predicting outcomes of lung adenocarcinoma.
    Yang Q; Zhu W; Gong H
    Front Immunol; 2023; 14():1148483. PubMed ID: 37077919
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterization of genomic instability-related genes predicts survival and therapeutic response in lung adenocarcinoma.
    Li S; Wang W; Yu H; Zhang S; Bi W; Sun S; Hong B; Fang Z; Chen X
    BMC Cancer; 2023 Nov; 23(1):1115. PubMed ID: 37974107
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.